GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » Net Income From Continuing Operations

Clover Biopharmaceuticals (HKSE:02197) Net Income From Continuing Operations : HK$-965.41 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Clover Biopharmaceuticals's net income from continuing operations for the six months ended in Dec. 2024 was HK$-863.01 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-965.41 Mil.

Clover Biopharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Clover Biopharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals Net Income From Continuing Operations Chart

Clover Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
Get a 7-Day Free Trial -1,082.18 -7,366.77 -2,738.08 -151.53 -964.57

Clover Biopharmaceuticals Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,469.39 711.64 -863.17 -102.40 -863.01

Clover Biopharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-965.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clover Biopharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » Net Income From Continuing Operations
Comparable Companies
HKSE:02257 HKSE:00690 HKSE:09939 HKSE:08158 HKSE:02185 HKSE:06628 HKSE:01228 HKSE:02126 HKSE:02496 HKSE:02898 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No. 758 West Nanjing Road, Room 1901, Jing’an District, Shanghai, CHN
Website
https://www.cloverbiopharma.com
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.
Executives
Liang Peng 2101 Beneficial owner
Liang Joshua G 2501 Other
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Aut-xxi Investment Holdings Limited 2201 Interest of corporation controlled by you
Jnry V Holdings Limited 2101 Beneficial owner
Aut-xxi Hk Holdings Limited 2101 Beneficial owner
Aut-xxi Holdings Limited 2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Super Novel International Limited 2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals Headlines

No Headlines